This morning, Trovagene (NASDAQ:TROV) announced it has entered into a clinical collaboration agreement with the University of Southern California study the effectiveness of the company's cell-free DNA assay. The goal is to show that Trovagene's technology is able to identify the cancer's genomic changes following treatment and to track the progression of the disease. On the news, shares of Trovagene were higher by 1.1%.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.